Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Dextromethorphan · Nuedexta

Small molecule · Agonist of sigma-1 receptor (SIGMAR1) and NMDA receptor (GRIN1) · developed by Otsuka America Pharm

Approved FDA, Oct 2010

1 Registered trials

What is Dextromethorphan?

Dextromethorphan is a sigma-1 receptor agonist and uncompetitive NMDA receptor antagonist. The exact mechanism by which it exerts therapeutic effects in pseudobulbar affect is unknown.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Nuedexta
Drug type: Small molecule
Targets: sigma-1 receptor (SIGMAR1), NMDA receptor (GRIN1)
Mechanism: Agonist of sigma-1 receptor (SIGMAR1) and NMDA receptor (GRIN1)
Therapy area: Infectious disease, Respiratory
Developer: Otsuka America Pharm
In trials of: PRGO
FDA status: Approved as Nuedexta (October 29, 2010), NDA021879 · FDA label

✅ FDA-approved uses

Pseudobulbar affect

From the indications section of the FDA label (version of Jan 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01257542	Phase 4	Common Cold	Terminated	PRGO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Common ColdInfections, Upper Respiratory Tract

Other drugs acting on SIGMAR1 / GRIN1

Dextromethorphan/Bupropion FDA approved L-4-chlorokynurenine Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z